脓毒症患者β-内酰胺类抗生素延长输注与间歇输注比较:随机临床试验的系统评价及荟萃分析与试验序贯分析
该系统评价纳入9项随机临床试验共1762例脓毒症患者,比较β-内酰胺类抗生素延长静脉输注与间歇静脉输注。汇总结果显示,延长输注组30天全因死亡率显著降低(RR 0.82;95%CI 0.70-0.96;P=0.01;TSA校正CI 0.62-1.07),医院死亡率、ICU死亡率更低,临床治愈率更高;90天死亡率及耐药菌出现无显著差异。证据确定性评为低,试验序贯分析提示需更多研究以进一步确认结论,长期生存获益未能显示改善。
要点
- 脓毒症患者延长输注β-内酰胺类抗生素较间歇输注降低30天全因死亡率(RR 0.82;95%CI 0.70-0.96;P=0.01;TSA校正CI 0.62-1.07)。
- 延长输注组医院死亡率、ICU死亡率更低,临床治愈率更高。
- 90天死亡率及耐药菌出现方面,延长输注与间歇输注无显著差异。
- 证据确定性评为低,试验序贯分析提示需更多研究才能得出确定性结论。
- 长期生存获益未能显示改善。
适用人群与场景
- 脓毒症患者(纳入9项随机临床试验共1762例患者)。
研究设计与关键结果
- 研究类型:随机临床试验的系统评价与荟萃分析及试验序贯分析;检索EMBASE、PubMed、Cochrane Library(截至2023年7月6日),共鉴定4355项研究,最终纳入9项研究1762例患者。
- 主要终点:与间歇静脉输注相比,延长静脉输注β-内酰胺类抗生素显著降低脓毒症患者30天全因死亡率(RR 0.82;95%CI 0.70-0.96;P=0.01;TSA校正CI 0.62-1.07)。
- 次要终点:延长输注与更低的医院死亡率、ICU死亡率和更高的临床治愈率相关;90天死亡率或耐药菌出现方面两组无显著差异。
- 证据确定性:评为低;试验序贯分析提示需更多研究以进一步确认结论。
证据类型、等级与局限
- 证据类型:随机临床试验的系统评价与荟萃分析及试验序贯分析。
- 证据确定性评为低。
- 局限:试验序贯分析提示需更多研究以进一步确认结论;长期生存获益未能显示改善。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The prolonged β-lactam antibiotics infusion has been an attractive strategy in severe infections, because it provides a more stable free drug concentration and a longer duration of free drug concentration above the minimum inhibitory concentration (MIC). We conducted this systematic review of randomized clinical trials (RCTs) with meta-analysis and trial sequential analysis (TSA) to compare the effects of prolonged vs intermittent intravenous infusion of β-lactam antibiotics for patients with sepsis.
METHODS: This study was prospectively registered on PROSPERO database (CRD42023447692). We searched EMBASE, PubMed, and Cochrane Library to identify eligible studies (up to July 6, 2023). Any study meeting the inclusion and exclusion criteria would be included. The primary outcome was all-cause mortality within 30 days. Two authors independently screened studies and extracted data. When the I2 values < 50%, we used fixed-effect mode. Otherwise, the random effects model was used. TSA was also performed to search for the possibility of false-positive (type I error) or false-negative (type II error) results.
RESULTS: A total of 4355 studies were identified in our search, and nine studies with 1762 patients were finally included. The pooled results showed that, compared with intermittent intravenous infusion, prolonged intravenous infusion of beta-lactam antibiotics resulted in a significant reduction in all-cause mortality within 30 days in patients with sepsis (RR 0.82; 95%CI 0.70-0.96; P = 0.01; TSA-adjusted CI 0.62-1.07). However, the certainty of the evidence was rated as low, and the TSA results suggested that more studies were needed to further confirm our conclusion. In addition, it is associated with lower hospital mortality, ICU mortality, and higher clinical cure. No significant reduction in 90-day mortality or the emergence of resistance bacteria was detected between the two groups.
CONCLUSIONS: Prolonged intravenous infusion of beta-lactam antibiotics in patients with sepsis was associated with short-term survival benefits and higher clinical cure. However, the TSA results suggested that more studies are needed to reach a definitive conclusion. In terms of long-term survival benefits, we could not show an improvement.
参考来源
- Li X, Long Y, Wu G, et al. Prolonged vs intermittent intravenous infusion of β-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. Ann Intensive Care. 2023. PMID: 38051467. doi:10.1186/s13613-023-01222-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。